This company has been marked as potentially delisted and may not be actively trading. NASDAQ:KERX Keryx Biopharmaceuticals (KERX) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About Keryx Biopharmaceuticals Stock (NASDAQ:KERX) 30 days 90 days 365 days Advanced Chart Get KERX alerts:Sign Up Key Stats Today's Range$2.97▼$3.4750-Day Range N/A52-Week Range$2.47▼$5.98Volume2.60 million shsAverage Volume1.69 million shsMarket Capitalization$344.00 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewKeryx Biopharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on providing medicines for patients with kidney disease in the United States. It markets its lead product Auryxia (ferric citrate), an orally available, absorbable, iron-based medicine for the control of serum phosphorus levels in patients with chronic kidney disease (CKD) on dialysis, as well as for the treatment of iron deficiency anemia in adults with CKD not on dialysis. The company has strategic alliances with Japan Tobacco Inc. and Torii Pharmaceutical Co., Ltd. for the development and commercialization of ferric citrate in Japan; and with Panion & BF Biotech, Inc. for the development and marketing of ferric citrate. Keryx Biopharmaceuticals, Inc. was founded in 1997 and is headquartered in Boston, Massachusetts.Read More… Receive KERX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Keryx Biopharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address KERX Stock News HeadlinesLBTI Lithium & Boron Technology, Inc.September 24, 2024 | seekingalpha.com2024 Biopharmaceutical Industry LandscapeAugust 17, 2024 | morningstar.comA grave, grave error.I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we are, a quarter of a century later, almost to the exact day, and it’s happening again. May 29, 2025 | Porter & Company (Ad)Caliway Biopharmaceuticals Co Ltd 6919April 13, 2024 | morningstar.comXTL Biopharmaceuticals Ltd ADR XTLBNovember 15, 2023 | morningstar.comImmuneOnco Biopharmaceuticals Shanghai Inc (1541)September 11, 2023 | investing.comQ2 2023 Westrock Coffee Co Earnings CallAugust 13, 2023 | finance.yahoo.comKeryx CEO vs. a Short-Seller: Zerenex Patent DebateJuly 29, 2023 | thestreet.comSee More Headlines KERX Stock Analysis - Frequently Asked Questions How were Keryx Biopharmaceuticals' earnings last quarter? Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX) announced its quarterly earnings results on Thursday, November, 8th. The biopharmaceutical company reported ($0.14) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.15) by $0.01. The biopharmaceutical company had revenue of $28.04 million for the quarter, compared to analysts' expectations of $29.56 million. What other stocks do shareholders of Keryx Biopharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Keryx Biopharmaceuticals investors own include Synergy Pharmaceuticals (SGYP), Bristol-Myers Squibb (BMY), Amyris (AMRS), Gilead Sciences (GILD), Exelixis (EXEL), Meta Platforms (META) and Immunomedics (IMMU). Company Calendar Last Earnings11/08/2018Today5/28/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical Preparations Sub-IndustryBiotechnology Current SymbolNASDAQ:KERX CIK1114220 Webwww.keryx.com Phone617-466-3500FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)($0.88) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$163.44 million Net Margins-96.41% Pretax MarginN/A Return on EquityN/A Return on Assets-60.05% Debt Debt-to-Equity RatioN/A Current Ratio2.21 Quick Ratio1.19 Sales & Book Value Annual Sales$60.64 million Price / Sales5.67 Cash FlowN/A Price / Cash FlowN/A Book Value($0.12) per share Price / Book-28.00Miscellaneous Outstanding Shares102,380,000Free FloatN/AMarket Cap$344.00 million OptionableOptionable Beta2.35 Investing Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free Report This page (NASDAQ:KERX) was last updated on 5/29/2025 by MarketBeat.com Staff From Our PartnersWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | SponsoredA grave, grave error.I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredTrump Exec Order 14179 is wealth “gift” to good Americans?Is President Trump’s Executive Order 14179… A secret way to restore wealth for good citizens? If you’ve ...Paradigm Press | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredTrump Predicts Dollar DownfallREAD THIS VERY CAREFULLY: If you have $100,000 or more saved for retirement, this may make you VERY angry... ...Augusta Precious Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Keryx Biopharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Keryx Biopharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.